Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Tilianin Inhibits MUC5AC Expression Mediated Via Down-Regulation of EGFR-MEK-ERK-Sp1 Signaling Pathway in NCI-H292 Human Airway Cells

  • Song, Won-Yong (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Song, Yong-Seok (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Ryu, Hyung Won (Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Oh, Sei-Ryang (Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Hong, JinTae (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yoon, Do-Young (Department of Bioscience and Biotechnology, Konkuk University)
  • Received : 2016.10.06
  • Accepted : 2016.10.26
  • Published : 2017.01.28
Download PDF
⟨ Previous Next ⟩

Abstract

In the human airway, mucus exists to protect the respiratory system as a primary barrier of the innate immune system. However, hyperexpressed mucus limits airflow, resulting in a decrease of lung function. Among more than 20 mucin family members, MUC5AC and MUC5B are major glycoproteins in human airway mucus. The epidermal growth factor receptor (EGFR) signaling pathway is one of the mechanisms of these mucins expression and specificity protein-1 (Sp1) transcription factor is the downstream signal of this pathway, playing pivotal roles in mucin expression. Even though there are some drugs for treating mucus hypersecretion, no drug has proven effects on humans. We found that the flavonoid tilianin regulated MUC5AC expression and also inhibited Sp1 phosphorylation. In this study, we investigated how tilianin would modulate EGFR signaling and regulate mucin production. In conclusion, tilianin inhibited MUC5AC expression mediated via modulating the EGFR-MEK-ERK-Sp1 signaling pathway in NCI-H292 human airway epithelial cells. This study may provide the basis for the novel treatment of mucus hypersecretion.

Keywords

References

  1. World Health Organisation. 2015. Chronic obstructive pulmonary disease (COPD). Available from http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed 25 August, 2016.
  2. Rogers DF, Barnes PJ. 2006. Treatment of airway mucus hypersecretion. Ann. Med. 38: 116-125. https://doi.org/10.1080/07853890600585795
  3. Martin C, Frija-Masson J, Burgel PR. 2014. Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs 74: 1073-1089. https://doi.org/10.1007/s40265-014-0235-3
  4. Burgel PR, Nadel JA. 2008. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur. Respir. J. 32: 1068-1081. https://doi.org/10.1183/09031936.00172007
  5. Casalino-Matsuda SM, Monzon ME, Forteza RM. 2006. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am. J. Respir. Cell Mol. Biol. 34: 581-591. https://doi.org/10.1165/rcmb.2005-0386OC
  6. Theodoropoulos G, Carraway KL. 2007. Molecular signaling in the regulation of mucins. J. Cell. Biochem. 102: 1103-1116. https://doi.org/10.1002/jcb.21539
  7. Hewson CA, Edbrooke MR, Johnston SL. 2004. PMA induces the MUC5AC respiratory mucin in human bronchial epithelial cells, via PKC, EGF/TGF-alpha, Ras/Raf, MEK, ERK and Sp1-dependent mechanisms. J. Mol. Biol. 344: 683-695. https://doi.org/10.1016/j.jmb.2004.09.059
  8. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. 2002. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J. Biol. Chem. 277: 32258-32267. https://doi.org/10.1074/jbc.M204862200
  9. Shikov AN, Pozharitskaya ON, Makarov VG, Wagner H, Verpoorte R, Heinrich M. 2014. Medicinal plants of the Russian Pharmacopoeia; their history and applications. J. Ethnopharmacol. 154: 481-536. https://doi.org/10.1016/j.jep.2014.04.007
  10. Sarkhail P. 2014. Traditional uses, phytochemistry and pharmacological properties of the genus Peucedanum: a review. J. Ethnopharmacol. 156: 235-270. https://doi.org/10.1016/j.jep.2014.08.034
  11. Martinez-Frances V, Rivera D, Heinrich M, Obon C, Rios S. 2015. An ethnopharmacological and historical analysis of "Dictamnus", a European traditional herbal medicine. J. Ethnopharmacol. 175: 390-406. https://doi.org/10.1016/j.jep.2015.09.011
  12. Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA, Martinez JA. 2009. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm. Res. 58: 537-552. https://doi.org/10.1007/s00011-009-0037-3
  13. Romano B, Pagano E, Montanaro V, Fortunato AL, Milic N, Borrelli F. 2013. Novel insights into the pharmacology of flavonoids. Phytother. Res. 27: 1588-1596. https://doi.org/10.1002/ptr.5023
  14. Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralhao JG, Botelho MF. 2015. Quercetin in cancer treatment, alone or in combination with conventional therapeutics? Curr. Med. Chem. 22: 3025-3039. https://doi.org/10.2174/0929867322666150812145435
  15. Wang L, Yang R, Yuan B, Liu Y, Liu C. 2015. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm. Sin. B 5: 310-315. https://doi.org/10.1016/j.apsb.2015.05.005
  16. Oh Y, Lim HW, Huang YH, Kwon HS, Jin CD, Kim K, et al. 2016. Attenuating properties of Agastache rugosa leaf extract against ultraviolet-B-induced photoaging via up-regulating glutathione and superoxide dismutase in a human keratinocyte cell line. J. Photochem. Photobiol. B 163: 170-176. https://doi.org/10.1016/j.jphotobiol.2016.08.026
  17. Desta KT, Kim GS, Kim YH, Lee WS, Lee SJ, Jin JS, et al. 2016. The polyphenolic profiles and antioxidant effects of Agastache rugosa Kuntze (Banga) flower, leaf, stem and root. Biomed. Chromatogr. 30: 225-231. https://doi.org/10.1002/bmc.3539
  18. Nam KH, Choi JH, Seo YJ, Lee YM, Won YS, Lee MR, et al. 2006. Inhibitory effects of tilianin on the expression of inducible nitric oxide synthase in low density lipoprotein receptor deficiency mice. Exp. Mol. Med. 38: 445-452. https://doi.org/10.1038/emm.2006.52
  19. Tuan PA, Park WT, Xu H, Park NI, Park SU. 2012. Accumulation of tilianin and rosmarinic acid and expression of phenylpropanoid biosynthetic genes in Agastache rugosa. J. Agric. Food Chem. 60: 5945-5951. https://doi.org/10.1021/jf300833m
  20. Berger JT, Voynow JA, Peters KW, Rose MC. 1999. Respiratory carcinoma cell lines. MUC genes and glycoconjugates. Am. J. Respir. Cell Mol. Biol. 20: 500-510. https://doi.org/10.1165/ajrcmb.20.3.3383
  21. Mitin N, Rossman KL, Der CJ. 2005. Signaling interplay in Ras superfamily function. Curr. Biol. 15: R563-R574. https://doi.org/10.1016/j.cub.2005.07.010
  22. Hsu YL, Kuo PL, Liu CF, Lin CC. 2004. Acacetin-induced cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. Cancer Lett. 212: 53-60. https://doi.org/10.1016/j.canlet.2004.02.019
  23. Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S. 2005. Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer 50: 19-24. https://doi.org/10.1016/j.lungcan.2005.05.005
  24. Fujisawa T, Velichko S, Thai P, Hung LY, Huang F, Wu R. 2009. Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm. J. Immunol. 183: 6236-6243. https://doi.org/10.4049/jimmunol.0900614
  25. Nam KW, Kim J, Hong JJ, Choi JH, Mar W, Cho MH, et al. 2005. Inhibition of cytokine-induced IkappaB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice. Atherosclerosis 180: 27-35. https://doi.org/10.1016/j.atherosclerosis.2004.11.022
  26. Feng J, Zhang Y, Xing D. 2012. Low-power laser irradiation (LPLI) promotes VEGF expression and vascular endothelial cell proliferation through the activation of ERK/Sp1 pathway. Cell Signal. 24: 1116-1125. https://doi.org/10.1016/j.cellsig.2012.01.013
  27. Tan NY, Khachigian LM. 2009. Sp1 phosphorylation and its regulation of gene transcription. Mol. Cell Biol. 29: 2483-2488. https://doi.org/10.1128/MCB.01828-08
  28. Kang JH, L ee EH, Park SW, Chung IY. 2011. MUC5AC expression through bidirectional communication of Notch and epidermal growth factor receptor pathways. J. Immunol. 187: 222-229. https://doi.org/10.4049/jimmunol.1003606
  29. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. 2015. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43: D805-D811. https://doi.org/10.1093/nar/gku1075
  30. Rossi G, Gasser B, Sartori G, Migaldi M, Costantini M, Mengoli MC, et al. 2012. MUC5AC, cytokeratin 20 and HER2 expression and K-RAS mutations within mucinogenic growth in congenital pulmonary airway malformations. Histopathology 60: 1133-1143. https://doi.org/10.1111/j.1365-2559.2011.04170.x
  31. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. 2014. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7: 86-93. https://doi.org/10.1016/j.celrep.2014.02.045
  32. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, et al. 2012. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11: 1143-1154. https://doi.org/10.1158/1535-7163.MCT-11-1010
  33. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, et al. 2008. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol. Pharmacol. 73: 1290-1300. https://doi.org/10.1124/mol.107.042382
  34. Shao MX, Ueki IF, Nadel JA. 2003. Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc. Natl. Acad. Sci. USA 100: 11618-11623. https://doi.org/10.1073/pnas.1534804100
  35. Spengler ML, Guo LW, Brattain MG. 2008. Phosphorylation mediates Sp1 coupled activities of proteolytic processing, desumoylation and degradation. Cell Cycle 7: 623-630. https://doi.org/10.4161/cc.7.5.5402
  36. Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE. 1999. An N-terminal region of Sp1 targets its proteasomedependent degradation in vitro. J. Biol. Chem. 274: 15194-15202. https://doi.org/10.1074/jbc.274.21.15194
  37. Merchant JL, Du M, Todisco A. 1999. Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem. Biophys. Res. Commun. 254: 454-461. https://doi.org/10.1006/bbrc.1998.9964
  38. Lee JA, Suh DC, Kang JE, Kim MH, Park H, Lee MN, et al. 2005. Transcriptional activity of Sp1 is regulated by molecular interactions between the zinc finger DNA binding domain and the inhibitory domain with corepressors, and this interaction is modulated by MEK. J. Biol. Chem. 280: 28061-28071. https://doi.org/10.1074/jbc.M414134200

Cited by

  1. Characterization of the human mucin 5AC promoter and its regulation by the histone acetyltransferase P300 vol.43, pp.3, 2017, https://doi.org/10.3892/ijmm.2019.4054
  2. Guifu Dihuang Pills Ameliorated Mucus Hypersecretion by Suppressing Muc5ac Expression and Inactivating the ERK-SP1 Pathway in Lipopolysaccharide/Cigarette Smoke-Induced Mice vol.2021, pp.None, 2017, https://doi.org/10.1155/2021/9539218